Business
Decision Diagnostics Corp. Announces Election of Two Key Managers to the Board of Its Korean Partner ''The Bio Co, Ltd.''
Decision Diagnostics Corp. Announces Election of Two Key Managers to the Board of Its Korean Partner ''The Bio Co, Ltd.''.
About this update from Decision Diagnostics Corp
[{"type":"text","content":"DECN Also Reports Major Progress Toward the Completion of Clinical Trials Testing of Its Genchoice! Strip, Begins Final Preparations for International Product LaunchLOS ANGELES, CA / ACCESSWIRE / July 12, 2018 / Decision Diagnostics Corp. (OTC PINK: DECN) is a 16 year old, diabetes-focused bio-technology R&D firm, manufacturer, quality plan administrator, FDA registered medical device customer support organization, and exclusive worldwide sales and regulatory process agent for the GenUltimate! (\"Sunshine\") diabetes test strip, the internationally launched GenSure! (\"Feather\") diabetes test strip, and the clinical trial in process GenChoice! (\"Ladybug\"), the market ready PetSure! test strip for the diabetic testing of dogs and cats, and the panacea GenPrecis! (\"Dragonfly\") diabetes testing system, ready for clinical trials.Decision Diagnostics is excited to announce that two key executives, CEO Keith Berman and exclusive agent to DECN for Asia Daniel Y. Kim, have been elected to the Board of Directors of The Bio Co. Ltd., the company's partner for the manufacturing of and development of its test strips and meters. Decision Diagnostics may also have a third director elected at an upcoming date.Keith Berman, CEO of Decision Diagnostics Corp., stated \"Daniel Kim and I are thrilled to be joining the Board of Directors at \"The Bio,\" a venture funded corporation located in South Korea, that is owned and financed by prominent Korean venture funds and angel investors.\"\"The Bio\" currently manufacturers DECN's GenUltimate!, GenSure! and PetSure! products for the U.S. and International markets, along with managing the clinical trials for the company's GenChoice! product, ready for sale in International markets in the Fall of 2018, or within 21 days of the issuance of the clinical trials IRB report. Furthermore, \"The Bio\" has completed development of the company's GenPrecis! system product scheduled to begin in-house testing in August 2018 and to enter clinical trials in late Fall 2018.Adding to these new developments, DECN reports that the clinical trials for its GenChoice! product are proceeding according to plan. The U.S. FDA requires in-house and clinical testing of the new product as part of its 510K application process. DECN reports that the in-house testing was completed on June 27. The clinical testing with live s...